Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Jonathan Van Ness has been on a weight loss journey and he's sharing an update on how things are going so far. The Queer Eye ...
Coverage complications are not unusual in the U.S. health care system. But the challenge is magnified for these obesity ...
Ozempic, Mounjaro and Wegovy may not be the lightbulb, jet airplane or internet, but their impact is expected to be so ...
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...
Discover the hidden challenges Black women face in maintaining weight loss and learn powerful strategies for long-term ...
Discover the hidden medical causes, psychological factors, and lifestyle changes that may explain the reasons for the unexpectedly weight loss.
Few big pharma stocks have been bigger winners over the last three years than Eli Lilly and Novo Nordisk. Lilly now ranks as ...
While the outcomes can be positive, Consumer Reports warns there are important considerations, especially for older adults, ...
Overall, the five-year risk of requiring follow-up surgery was 5.6% for those who gained weight or kept their starting weight, 4.4% for those who lost a small to moderate amount of weight, and 3.7% ...
Shortages of Ozempic and Wegovy that have been in place for more than two years have been resolved, as supplies of obesity ...
President Donald Trump and HHS Secretary Robert F. Kennedy Jr. said they will be studying the "threat" to children posed by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results